microtubule disruptor

OSIP-486823(CP248) is a novel and potent microtubule disruptor with affinity for both protein kinase G (PKG) and microtubules.

ELR510444 (LR510444) is a novel microtubule disruptor; inhibits MDA-MB-231 cell proliferation with IC50 of 30.9 nM; not a substrate for the P-glycoprotein drug transporter and retains activity in βIII-tubulin-overexpressing cell lines.

THIQ-20c is a steroidomimetic and chimeric microtubule disruptor.

Microtubule Inhibitor 8 (MP-HJ-1b) serves as a potent disruptor of microtubule function, inducing cell death via ferroptosis and demonstrating anti-tumor effects [1] [2].

Indusatumab vedotin is an antibody-drug conjugate (ADC) consisting of an antibody targeting human guanylate cyclase C (GCC) conjugated with the microtubule inhibitor monomethyl auristatin. It can inhibit the proliferation of pancreatic cancer cells, arrest the cell cycle at G2/M phase, and induce apoptosis.

Colchicine-D3 is the deuterated form of Colchicine. Colchicine (T0320) acts as a microtubule protein (tubulin) inhibitor and disruptor of microtubules (microtubule), with an IC50 of 3 nM for inhibiting microtubule polymerization. Additionally, Colchicine (T0320) serves as a competitive antagonist of the α3 glycine receptor (GlyRs).

(R)-Colchicine is the R-isomer of Colchicine. Colchicine is an orally active alkaloid that serves as an effective microtubule protein inhibitor and disruptor. It inhibits microtubule polymerization with an IC50 of 3 nM and acts as a competitive antagonist of the α3 glycine receptor (GlyR). Additionally, Colchicine prevents NSAID-induced small intestinal injury by inhibiting the activation of the NLRP3 inflammasome. It exhibits extensive anti-inflammatory, immunosuppressive, and potent antifibrotic effects, with potential applications in gouty arthritis research.